Genetics May Help Predict Who Benefits Most From Pancreas Transplant Surgery

Total pancreatectomy with islet autotransplantation (TPIAT) is a procedure for people with chronic pancreatitis—a long-term inflammation of the pancreas. The surgery removes the entire pancreas and then takes the insulin-producing cells (islets) from that pancreas and puts them back into the patient's body, usually into the liver. The goal is to preserve the body's ability to make insulin and avoid lifelong insulin injections.

Success varies widely. About one in five patients becomes insulin-independent—meaning they no longer need insulin shots—within a year after surgery. Doctors have known that younger patients and those with better blood sugar control before surgery tend to do better, but they haven't fully understood why some people respond better than others.

Researchers studied 318 patients with chronic pancreatitis who underwent TPIAT to see whether genetic factors could predict how well they'd recover. They looked at genetic risk scores—estimates of disease risk based on thousands of genetic markers—related to both type 1 and type 2 diabetes, as well as scores linked to beta-cell function (the cells that make insulin).

The study found that genetic markers associated with type 2 diabetes were more common in patients who already had diabetes before their transplant. Additionally, these type 2 diabetes genetic scores were linked to higher blood sugar levels (HbA1c) before surgery.

A genetic score related to beta-cell function predicted how much insulin patients needed after transplant and how well their blood sugar was controlled when accounting for their insulin dose. Patients with genetic factors suggesting weaker beta cells tended to require more insulin after surgery.

This study is among the first to show that genetics can help explain differences in how well TPIAT works for individual patients. The findings suggest that genetic testing before surgery might one day help doctors predict which patients are more likely to succeed and regain insulin independence.

However, genetics is only part of the story. Age, blood sugar control before surgery, and the number of healthy islets transplanted remain crucial factors. The study doesn't change how TPIAT is performed today—rather, it opens the door to better understanding why outcomes vary and potentially personalizing care in the future.

This research was part of a larger prospective study funded by the National Institutes of Health tracking TPIAT outcomes across multiple medical centers. The 318 participants were on average 29 years old, 61% were female, and 84% were non-Hispanic White. Only 13% had diabetes before their transplant—most were being treated for chronic pancreatitis pain and complications.

These findings apply specifically to people undergoing TPIAT for chronic pancreatitis, not to people with type 1 diabetes seeking new treatment options. TPIAT remains a specialized procedure with significant risks and benefits that must be carefully weighed with each patient's medical team.

Source: The Journal of clinical endocrinology and metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.